Insmed (INSM) Tops Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P, Dow edge higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Insmed Reports First Quarter 2022 Financial Results and Provides Business Update
May 5, 2022 7:30 AM EDT--ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 32% Year Over Year Growth for the First Quarter of 2022 with Total Revenue of $53.1 Million--
--Seven Clinical Trials Underway; Enrollment on Track in Brensocatib Phase 3 ASPEN Study and ARIKAYCE Post-Marketing Studies (ARISE and ENCORE)--
--Company Reiterates Revenue Guidance of at Least 30% Growth in 2022 and Cash Runway into 2024 to Support Ongoing Programs--
BRIDGEWATER, N.J., May 5, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the... More
